BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 30658428)

  • 1. Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases.
    Whang YM; Jung SP; Kim MK; Chang IH; Park SI
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment.
    Hartmann S; Bhola NE; Grandis JR
    Clin Cancer Res; 2016 Aug; 22(16):4005-13. PubMed ID: 27370607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways.
    Previdi S; Maroni P; Matteucci E; Broggini M; Bendinelli P; Desiderio MA
    Eur J Cancer; 2010 Jun; 46(9):1679-91. PubMed ID: 20350802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic regulation of HGF/Met receptor axis is critical for the outgrowth of bone metastasis from breast carcinoma.
    Bendinelli P; Maroni P; Matteucci E; Desiderio MA
    Cell Death Dis; 2017 Feb; 8(2):e2578. PubMed ID: 28151481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of hepatocyte growth factor in the development of bone metastasis of a mouse mammary cancer cell line, BALB/c-MC.
    Ono K; Kamiya S; Akatsu T; Nakamura C; Li M; Amizuka N; Matsumoto K; Nakamura T; Kugai N; Wada S
    Bone; 2006 Jul; 39(1):27-34. PubMed ID: 16459153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-Osteoblasts Stimulate Migration of Breast Cancer Cells via the HGF/MET Pathway.
    Vallet S; Bashari MH; Fan FJ; Malvestiti S; Schneeweiss A; Wuchter P; Jäger D; Podar K
    PLoS One; 2016; 11(3):e0150507. PubMed ID: 26934743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In bone metastasis miR-34a-5p absence inversely correlates with Met expression, while Met oncogene is unaffected by miR-34a-5p in non-metastatic and metastatic breast carcinomas.
    Maroni P; Puglisi R; Mattia G; Carè A; Matteucci E; Bendinelli P; Desiderio MA
    Carcinogenesis; 2017 May; 38(5):492-503. PubMed ID: 28334277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone-targeting agents in prostate cancer.
    Suzman DL; Boikos SA; Carducci MA
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):619-28. PubMed ID: 24398856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications.
    García-Vilas JA; Medina MÁ
    World J Gastroenterol; 2018 Sep; 24(33):3695-3708. PubMed ID: 30197476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of the HGF/Met signaling in head and neck squamous cell carcinoma: Focus on tumor immunity (Review).
    Liu D; Zhong M; Zhan D; Zhang Y; Liu S
    Oncol Rep; 2020 Dec; 44(6):2337-2344. PubMed ID: 33125120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.
    Fujita H; Gomori A; Fujioka Y; Kataoka Y; Tanaka K; Hashimoto A; Suzuki T; Ito K; Haruma T; Yamamoto-Yokoi H; Harada N; Sakuragi M; Oda N; Matsuo K; Inada M; Yonekura K
    PLoS One; 2016; 11(10):e0164830. PubMed ID: 27736957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wenshen Zhuanggu formula mitigates breast cancer bone metastasis through the signaling crosstalk among the Jagged1/Notch, TGF-β and IL-6 signaling pathways.
    Wu C; Chen M; Sun Z; Ye Y; Han X; Qin Y; Liu S
    J Ethnopharmacol; 2019 Mar; 232():145-154. PubMed ID: 30576770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HGF-met signaling axis: emerging themes and targets of inhibition.
    Steffan JJ; Coleman DT; Cardelli JA
    Curr Protein Pept Sci; 2011 Feb; 12(1):12-22. PubMed ID: 21190524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the hepatocyte growth factor/Met pathway in cancer.
    De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
    Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia.
    Giannoni P; Cutrona G; Totero D
    Curr Mol Med; 2017; 17(1):24-33. PubMed ID: 28231754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma macrophage-stimulating protein and hepatocyte growth factor levels are associated with prostate cancer progression.
    Sugie S; Mukai S; Yamasaki K; Kamibeppu T; Tsukino H; Kamoto T
    Hum Cell; 2016 Jan; 29(1):22-9. PubMed ID: 26250899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis.
    Lee C; Whang YM; Campbell P; Mulcrone PL; Elefteriou F; Cho SW; Park SI
    Cancer Lett; 2018 Feb; 414():205-213. PubMed ID: 29174801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice.
    Sakamoto S; Inoue H; Ohba S; Kohda Y; Usami I; Masuda T; Kawada M; Nomoto A
    Cancer Sci; 2015 Apr; 106(4):367-74. PubMed ID: 25640943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dysregulation of HGF/c-Met signal pathway and their targeting drugs in lung cancer].
    Li Y; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2014 Aug; 17(8):625-34. PubMed ID: 25130970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.